[go: up one dir, main page]

WO2001064167A1 - Preparations cosmetiques et pharmaceutiques destinees au traitement de la cellulite - Google Patents

Preparations cosmetiques et pharmaceutiques destinees au traitement de la cellulite Download PDF

Info

Publication number
WO2001064167A1
WO2001064167A1 PCT/EP2001/002071 EP0102071W WO0164167A1 WO 2001064167 A1 WO2001064167 A1 WO 2001064167A1 EP 0102071 W EP0102071 W EP 0102071W WO 0164167 A1 WO0164167 A1 WO 0164167A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
preparation
preparation according
cosmetic
substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2001/002071
Other languages
German (de)
English (en)
Inventor
Ulrich Issberner
Marcus Claas
Vera Maienschein
Silke Nieveler
Thomas Förster
Werner Köhl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Henkel AG and Co KGaA
Original Assignee
Henkel AG and Co KGaA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henkel AG and Co KGaA filed Critical Henkel AG and Co KGaA
Priority to EP01907556A priority Critical patent/EP1261310A1/fr
Priority to AU2001235491A priority patent/AU2001235491A1/en
Publication of WO2001064167A1 publication Critical patent/WO2001064167A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists

Definitions

  • the invention relates to cosmetic and pharmaceutical preparations containing a substance that stimulates and / or depolarizes C-nerve fibers, a phosphodiesterase inhibitor and a substance with an anti-estrogenic effect.
  • the preparations are particularly suitable for treating cellulite.
  • Cellulite (synonyms: panniculosis, lipodystrophy, status protrusis cutis, orange peel) is a local accumulation of fat and water in body tissue. It is a predominantly aesthetic problem associated with pitting and deepening of the skin and nodulation of the subcutaneous fatty tissue, particularly on the thighs and buttocks. In advanced stages of cellulite, pain in the area of the nodules can also occur. A clear distinction from cellulite is cellulitis (panniculitis), which is an inflammation of the subcutaneous adipose tissue and thus a serious and life-threatening illness in some cases.
  • cellulite The causes of cellulite are not exactly known. However, it is usually considered a cosmetic problem. However, there are also voices in the specialist literature that regard cellulite as a pathological condition that requires therapy. This approach is based on the one hand on pain conditions, which have their origin especially in the area of the strongly greased subcutaneous tissue. On the other hand, the psychological stress associated with cellulite can manifest itself in psychosomatic disorders that require treatment.
  • the conventional treatment methods for cellulite try to promote blood circulation and have a positive influence on the connective tissue structure, for example through
  • the best known and most widespread of the methods of stimulating lipolysis is to inhibit the enzyme phosphodiesterase in order to prevent or at least slow down the degradation of the cyclic AMP.
  • the phosphodiesterase destroys the cyclic AMP by converting it to 5 ' -AMP, which is no longer able to activate lipolysis. It is therefore important to inhibit the action of the phosphodiesterase in such a way that a high concentration of cyclic AMP is achieved in the region of the adipocytes with the aim of stimulating lipolysis.
  • various phosphodiesterase inhibitors that have been recommended, for example, as slimming agents, are the xanthine bases, especially caffeine.
  • Plant extracts, growth factors, inositol phosphate, alpha-hydroxycarboxylic acids and vitamin C were also recommended for the treatment of cellulite.
  • FR 2740681 describes cosmetic compositions for the treatment of cellulite which contain caffeine and an extract from the bark or leaves of plants of the genus Viburnum.
  • amentoflavone is described, one consisting of two apigenin units Biflavonoid.
  • amentoflavone is a characteristic ingredient of viburnum and serves to standardize the dosage of the viburnum extract in the compositions according to the invention. The document does not give the person skilled in the art any indication that the amentoflavone could be the cause or jointly responsible for the anti-cellulite effect of the compositions.
  • compositions with a local slimming effect which is attributed to their intracellular phosphodiesterase-inhibiting action.
  • the compositions may contain glycosides such as bioflavonoids as additional ingredients. It is not disclosed which substances or groups of substances are to be understood under the term bioflavonoids, which is known to be contradictory in the specialist world. This does not enable the person skilled in the art to prepare a composition according to the teaching of the writing containing a bioflavonoid which has a locally slimming effect. The document also gives no indication that the bioflavonoids could contribute to the slimming properties of the compositions according to the invention.
  • the object of the invention was to remedy the shortcomings of the prior art and to provide an improved agent for treating cellulite.
  • Another object of the invention was to provide an agent which combines an improved action against cellulite with an effect which is immediately noticeable when the agent is used and which gives the user the impression of an onset of action.
  • the object of the invention is achieved by cosmetic or pharmaceutical preparations which, in a physiologically compatible carrier, contain at least one substance which stimulates and / or depolarizes C-nerve fibers, at least one phosphodiesterase inhibitor and at least one substance with an anti-estrogenic effect.
  • the C-nerve fibers also called polymodal C-nerve fibers, play an important role in the human organism for the sensory functions of the Body, especially the skin. They are primarily involved in the perception of, for example, heat, cold and itching as well as the sensation of pain (e.g. heat pain, cold pain, stinging pain, burning pain).
  • the polymodal C-nerve fibers have a special position as a sub-group of the C-nerve fibers because they can react to several different stimuli and can also intervene in the stimulus process through the release of mediators.
  • Different receptors such as capsaicin, bradykinin and 5-hydroxytryptamine receptors are located on the surface of the C-nerve fibers, as well as ion channels such as calcium and sodium channels, via which the C-nerve fibers can be stimulated and / or depolarized.
  • This stimulation and / or depolarization triggers a sensory stimulus which manifests itself, for example, as a burning, tingling, sensation of warmth, cold or pain.
  • it is preferred to trigger a tingling sensation, a slight burning sensation or a feeling of warmth or coldness by stimulating and / or depolarizing the C-nerve fibers of the skin, in particular by stimulating the capsaicin receptors of these nerve fibers.
  • substances influencing C nerve fibers are to be understood, for example:
  • Preferred substances influencing C-nerve fibers are capsaicin, N-vanillyl nonanamide, their glycosides and mixtures thereof.
  • the substances influencing the C-nerve fibers sometimes have further desired effects. They promote the blood flow to the treated tissue and thus promote the penetration of the ingredients of the preparation into the skin. Furthermore, the removal of the degradation products which arise in the course of the lipolysis which is brought about by the use of the preparation can be promoted. In addition, the cellulite pain that occurs in severe cases can be reduced. This is the case, for example, when nonivamide is used as the substance influencing the C nerve fibers.
  • Suitable phosphodiesterase inhibitors in the preparations according to the invention are, for example, inhibitors as described in RM Di Salvo, Controlling the Appearance of Cellulite, Cosmetics and Toilet's Magazine HO, pp. 50-59 (1995) or in L. Stryer, Biochemistry, Spektrum Akademischer Verlag GmbH, Heidelberg 1991, p. 482.
  • Phosphodiesterase inhibitors preferred according to the invention are xanthine or methylxanthines, whereby a methylxanthine is a xanthine derivative in which one or more hydrogen atoms of the xanthine by methyl groups are replaced.
  • Theophylline, theobromine and caffeine are preferred as methylxanthines, and caffeine is particularly preferred.
  • the preparations according to the invention contain one or more substances with an anti-estrogenic effect.
  • Anti-estrogenic substances are substances that act in the organism as antagonists of estrogenic substances. This can happen, for example, in that an anti-estrogenic substance binds to estrogen receptors without, however, triggering an estrogenic effect.
  • the selection of anti-estrogenic substances is possible for the person skilled in the art by simple routine experiments and can be carried out, for example, by examining tissue and cell cultures that are sensitive to estrogen. Such experiments are described, for example, in Estrogen agonistic / antagonistic effects of miproxifene phosphate (TAT-59), Cancer Chemother. Pharmacol. 45 (2000), pp. 133-141 and J. Shibata et al., Hormonally active agents in food: Symposium Deutsche Anlagensisme, Verlag Wiley-VCH GmbH, Weinheim 1998, chap. 7, p. 4, 91, 93.
  • anti-estrogenic substances in the sense of the invention are tamoxifen, aminoglutethimide, clomiphene, testosterone, androsterone, isoflavones and isoflavone glycosides.
  • isoflavones are attributed to estrogenic effects, which is why they are also called phytoestrogens, but these substances are also known to have anti-estrogenic effects under certain conditions and in certain concentrations (hormonally active agents in food: symposium / German Research Foundation, Verlag Wiley-VCH, Weinheim 1998, pp. 25, 93).
  • preparations according to the invention they are preferably used in a concentration in which they exert an anti-estrogenic effect.
  • Preferred anti-estrogenic substances are isoflavones, isoflavone glycosides, tamoxifen and mixtures thereof.
  • isoflavones are understood to mean substances which are hydrogenation, oxidation or substitution products of 3-phenyl-4H-1-benzopyran, where hydrogenation can be present in the 2,3-position of the carbon skeleton, oxidation under Formation of a carbonyl group may be in the 4-position, and substitution is to be understood as the replacement of one or more hydrogen atoms by hydroxyl or methoxy groups.
  • the isoflavones according to the invention include, for example, daidzein, genistein, prunetin, biochanin, Orobol, Santal, pratensein, irigenin, glycitein, biochanin A and formononetin. Daidzein, genistein, glycitein and formononetin are preferred as isoflavones.
  • the isoflavones are glycosidically linked to at least one sugar via at least one hydroxyl group.
  • Suitable sugars are mono- or oligosaccharides, in particular D-glucose, D-galactose, D-glucuronic acid, D-galacturonic acid, D-xylose, D-apiose, L-rhamnose, L-arabinose and rutinose.
  • Preferred examples of the isoflavone glycosides according to the invention are daidzin and genistin.
  • the isoflavones and / or their glycosides are contained in the preparations as constituents of a mixture of substances obtained from a plant, in particular a plant extract.
  • a plant extract obtained from a plant, in particular a plant extract.
  • Such vegetable substance mixtures can be obtained in a manner familiar to the person skilled in the art, for example by pressing or extracting them from plants such as soybean, red clover or chickpeas.
  • Isoflavones or isoflavone glycosides in the form of extracts obtained from soy are particularly preferably used in the preparations according to the invention, such as those known under the product name Soy Protein Isolate SPI (Protein Technology International, St. Louis) or Soy Phytochemicals Concentrate SPC (Archer Daniels Midland, Decatur) are commercially available.
  • Alcohols and mixtures thereof can be used as extractants for the production of the plant extracts mentioned.
  • the alcohols are lower alcohols such as especially ethanol and isopropanol, and polyvalent
  • Alcohols such as ethylene glycol, propylene glycol and butylene glycol, both as the sole extracting agent and in a mixture with water, are preferred.
  • Alcoholic extraction is preferred according to the invention.
  • mixtures of several, in particular two, different plant extracts in the agents according to the invention may be preferred.
  • the active ingredients are used in the cosmetic or pharmaceutical preparations according to the invention in a concentration which is at most equal to the toxicologically permissible use concentration.
  • the cosmetic or pharmaceutical preparations contain
  • the cosmetic preparations preferably contain
  • the physiologically acceptable carrier of the cosmetic or pharmaceutical preparations comprises one or more auxiliaries, as are usually used in such preparations, such as.
  • auxiliaries such as.
  • the cosmetic preparations according to the invention are preferably suitable for the cosmetic treatment of cellulite and local excess fat, but also for so-called “slimming products” or skin-tightening products for legs, cleavage, neck or the face area.
  • the cosmetic and pharmaceutical preparations according to the invention are advantageously in the form of a liquid or solid oil-in-water emulsion, water-in-oil emulsion, multiple emulsion, microemulsion, PIT emulsion or Pickering emulsion, a hydrogel, an alcoholic gel, a lipogel, a single or multi-phase solution, a foam, an ointment, a plaster, a suspension, a powder or a mixture with at least one polymer suitable as a medical adhesive.
  • the skin treatment agents according to the invention can also be administered in anhydrous form, such as, for example, an oil or a balm.
  • the carrier can be a vegetable or animal oil, a mineral oil, a synthetic oil or a mixture of such oils.
  • the agents are in the form of a microemulsion.
  • microemulsions are understood to mean not only the thermodynamically stable microemulsions but also the so-called “PIT” emulsions. These emulsions are systems with the 3 components water, oil and emulsifier, which are present as an oil-in-water emulsion at room temperature.
  • phase inversion temperature converts to water-in-oil (W / 0) emulsions when heated further.
  • O / W emulsions are again formed, but these are also present at room temperature as microemulsions or as very fine-particle emulsions with an average particle diameter below 400 nm and in particular from about 100-300 nm.
  • those micro- or "PIT” emulsions can be preferred which have an average particle diameter of approximately 200 nm. Details regarding these "PIT emulsions” e.g. B. the publication Angew. Chem. 97, 655-669 (1985).
  • Suitable fat substances are for example:
  • vegetable oils such as sunflower oil, olive oil, soybean oil, rapeseed oil, almond oil, jojoba oil, orange oil, wheat germ oil, peach seed oil and the liquid components of coconut oil,
  • paraffin oils e.g. 1, 3-di- (2-ethyl-hexyl) cyclohexane (Cetiol ® S) or polydecene,
  • Di-n-alkyl ethers with a total of 12 to 36, in particular 12 to 24 carbon atoms, for.
  • di-n-octyl ether (Cetiol ® OE)
  • di-n-n-hexyl-n-octyl ether di-n-octyl-n-decyl ether.
  • C ⁇ o- 22 fatty acids are preferred.
  • examples are the isostearic acids and isopalmitic acids such as the fatty acids sold under the trade name Edenor ® .
  • Fatty acids are caprylic acid, 2-ethylhexanoic, capric acid, lauric acid, isotridecanoic, myristic acid, palmitic acid, stearic acid, isostearic acid, oleic acid, elaidic, Petroselin acid, linoleic acid, linolenic acid, eleostearic acid, arachidonic acid, Gadolein Textre, behenic acid and erucic acid and technical mixtures.
  • the fatty acid cuts that are obtainable from coconut oil or palm oil are usually particularly preferred; the use of stearic acid is particularly preferred.
  • Fatty alcohols especially saturated, mono- or polyunsaturated, branched or unbranched fatty alcohols with 6 - 30, preferably 10 - 22 and very particularly preferably 12 - 22 carbon atoms.
  • 6 - 30, preferably 10 - 22 and very particularly preferably 12 - 22 carbon atoms For the purposes of the invention, z. B.
  • Esteröle that is, esters of C 6 - 3 o-fatty acids with C 2-3 o-fatty alcohols.
  • the monoesters of fatty acids with alcohols having 2 to 24 carbon atoms are preferred.
  • the above-mentioned substances can be used as alcohol and acid components of the ester oils.
  • Hydroxycarboxylic acid alkyl esters wherein the Vollester of glycolic acid, lactic acid, malic acid, tartaric acid or citric acid are preferred, but also esters of beta-hydroxypropionic acid, tartronic acid, D-gluconic acid, saccharic acid, mucic acid or glucuronic acid are suitable and particularly preferred are the esters of C ⁇ 2 - C ⁇ 5 fatty alcohols, for. B.
  • Dicarboxylic acid esters such as di-n-butyl adipate, di- (2-ethylhexyl) adipate, di- (2-ethylhexyl) succinate and di-isotridecyl acelate as well as diol esters such as ethylene glycol dioleate, ethylene glycol di-isotridecanoate, propylene glycol di (2-ethyl hexanoate), propylene glycol -di-isostearate, propylene glycol-di-pelargonate, butanediol-di-isostearate, neopentyl glycol dicaprylate, symmetrical, asymmetrical or cyclic esters of carbonic acid with fatty alcohols, e.g. B. glycerol carbonate or dicaprylyl carbonate (Cetiol ®
  • Mono, - di- and trifatty acid esters of saturated and / or unsaturated linear and / or branched fatty acids with glycerol e.g. B. Monomuls ® 90-018, Monomuls ® 90-L12 or Cutina ® MD,
  • Waxes in particular insect waxes such as beeswax and bumblebee wax, plant waxes such as candelilla wax and carnauba wax, fruit waxes, ozone kerit, micro waxes, ceresin, paraffin, triglycerides saturated and optionally hydroxylated Ci 6 - 3 o-fatty acids, such as.
  • Silicone compounds selected from decamethylcyclopentasiloxane, dodecamethylcyclohexasiloxane and silicone polymers, which can, if desired, be cross-linked, e.g. B. polydialkylsiloxanes, polyalkylarylsiloxanes, ethoxylated polydialkylsiloxanes, preferably the substances with the INCI name Dimethicone Copolyol, and polydialkylsiloxanes containing amine and / or hydroxy groups.
  • the amount of fatty substances used is 0.1-50% by weight, preferably 0.1-20% by weight and particularly preferably 0.1-15% by weight, in each case based on the total composition.
  • the skin treatment compositions according to the invention can contain one or more surface-active substances as emulsifiers or dispersants.
  • Emulsifiers cause the formation of water or oil-stable adsorption layers that protect the dispersed droplets against coalescence and thus stabilize the emulsion.
  • emulsifiers are therefore made up of a hydrophobic and a hydrophilic part of the molecule.
  • Hydrophilic emulsifiers preferably form O / W emulsions and hydrophobic emulsifiers preferably form W / O emulsions.
  • W / O emulsions which are stabilized without hydrophilic emulsifiers are disclosed in the published documents DE 19816665 A1 and DE 19801593 A1.
  • An emulsion is to be understood as a droplet-like distribution (dispersion) of a liquid in another liquid with the use of energy to create stabilizing phase interfaces by means of surfactants.
  • the selection of these emulsifying surfactants or emulsifiers is based on the substances to be dispersed and the particular external phase as well as the fine particle size of the emulsion.
  • Emulsifiers which can be used according to the invention are, for example
  • alkyl (oligo) glucosides e.g. B. the commercially available product Montanov ® 68,
  • Sterols are understood to be a group of steroids which carry a hydroxyl group on the C atom 3 of the steroid structure and are isolated both from animal tissue (zoosterols) and from vegetable fats (phytosterols). Examples of zoosterols are cholesterol and lanosterol. Examples of suitable phytosterols are beta-sitosterol, stigmasterol, campesterol and ergosterol. Sterols, the so-called mycosterols, are also isolated from fungi and yeasts.
  • glucose phospholipids especially the glucose phospholipids, which, for. B. as lecithins or phosphatidylcholines from z. B. egg yolk or plant seeds (e.g. soybeans) are obtained,
  • polyglycerols and polyglycerol preferably Polyglyceryl-2-dipolyhydroxy- stearate (commercial product Dehymuls ® PGPH) and polyglyceryl-3 diisostearate (Lameform ® TGI commercial product)
  • the cosmetic and pharmaceutical preparations according to the invention preferably contain the emulsifiers in amounts of 0.1 to 25% by weight, in particular 0.5-15% by weight, based on the total composition.
  • the skin treatment agents according to the invention contain organic or mineral or modified mineral light protection filters.
  • the light protection filters are substances which are liquid or crystalline at room temperature and are able to absorb ultraviolet rays and absorb the energy in the form of longer-wave radiation, e.g. B. to release heat again.
  • the UVA and UVB filters can be used both individually and in mixtures. The use of filter mixtures is preferred according to the invention.
  • the organic UV filters used according to the invention are selected from the derivatives of dibenzoylmethane, cinnamic acid esters, diphenylacrylic acid esters, benzophenone, camphor, p-aminobenzoic acid esters, o-aminobenzoic acid esters, salicylic acid esters, benzimidazoles, 1, 3,5-triazines, monomeric and oligomeric 4,4- Diaryl butadiene carboxylic acid esters and carboxamides,
  • the organic UV filters can be oil-soluble or water-soluble.
  • particularly preferred oil-soluble UV filters are 1- (4-tert-butylphenyl) -3- (4'methoxyphenyl) propane-1, 3-dione (Parsol ® 1789), 1-phenyl-3- (4'-isopropylphenyl ) -propane-1, 3-dione, 3- (4 ' -methylbenzylidene) -D, L-camphor, 4- (dimethylamino) -benzoic acid-2-ethylhexyl ester, 4- (dimethylamino) benzoic acid-2-octyl ester, 4- (Dimethylamino) benzoic acid amyl ester, 4-methoxycinnamic acid, 2-ethylhexyl ester, 4-methoxycinnamic acid propy
  • Preferred water-soluble UV filters are 2-phenylbenzimidazole-5-sulfonic acid and its alkali, alkaline earth, ammonium, alkylammonium, alkanolammonium and glucammonium salts, sulfonic acid derivatives of benzophenones, preferably 2-hydroxy-4-methoxybenzophenone-5-sulfonic acid and their Salts, sulfonic acid derivatives of 3-benzylidene camphor, such as. B. 4- (2-oxo-3-bornylidene methyl) benzenesulfonic acid and 2-methyl-5- (2-oxo-3-bornylidene) sulfonic acid and their salts.
  • the inorganic light protection pigments preferred according to the invention are finely dispersed metal oxides and metal salts, for example titanium dioxide, zinc oxide, iron oxide, aluminum oxide, cerium oxide, zirconium oxide, silicates (talc), Barium sulfate and zinc stearate.
  • the particles should have an average diameter of less than 100 nm, preferably between 5 and 50 nm and in particular between 15 and 30 nm. They can have a spherical shape, but it is also possible to use particles which have an ellipsoidal shape or a shape which differs from the spherical shape in some other way.
  • the pigments can also be surface-treated, ie hydrophilized or hydrophobicized. Typical examples are coated titanium dioxide, such as. B.
  • Titanium dioxide T 805 (Degussa) or Eusolex ® T2000 (Merck). Silicones, and in particular trialkoxyoctylsilanes or simethicones, are particularly suitable as hydrophobic coating agents. So-called micro- or nanopigments are preferably used in sunscreens. Micronized zinc oxide is preferably used.
  • Contain protein hydrolyzates or their derivatives Contain protein hydrolyzates or their derivatives.
  • animal protein hydrolyzates are e.g. B. elastin, collagen, keratin, silk and milk protein protein hydrolyzates, which may also be in the form of salts.
  • Vegetable protein hydrolyzates e.g. B. soy, wheat, almond, pea, potato and rice protein hydrolyzates.
  • Corresponding commercial products are e.g. B. DiaMin ® (Diamalt), Gluadin ® (Cognis), Lexein ® (Inolex) and Crotein ® (Croda).
  • amino acid mixtures or individual amino acids such as arginine, lysine, histidine or pyrroglutamic acid, which have been obtained in some other way can also be used instead of them.
  • derivatives of protein hydrolyzates e.g. B. in the form of their fatty acid condensation products.
  • Corresponding commercial products are e.g. B. Lamepon ® (Cognis), Gluadin ® (Cognis), Lexein ® (Inolex), Crolastin ® or Crotein ® (Croda).
  • the additional protein hydrolyzates and their derivatives are in amounts of 0.01-10 % By weight based on the total composition. Amounts of 0.1 to 5% by weight, in particular 0.1 to 3% by weight, are particularly preferred.
  • the skin treatment compositions according to the invention can furthermore contain mono-, oligo- or polysaccharides or their derivatives.
  • Suitable monosaccharides according to the invention are e.g. B. glucose, fructose, galactose, arabinose, ribose, xylose, lyxose, allose, old rose, mannose, gulose, idose and talose, the deoxy sugar fucose and rhamnose and amino sugar such as.
  • Suitable oligosaccharides according to the invention are composed of two to ten monosaccharide units, for. B. sucrose, lactose or trehalose.
  • a particularly preferred oligosaccharide is sucrose.
  • honey which predominantly contains glucose and sucrose, is also particularly preferred.
  • Polysaccharides suitable according to the invention are composed of more than ten monosaccharide units.
  • Preferred polysaccharides are the starches made up of ⁇ -D-glucose units and starch degradation products such as amylose, amylopectin and dextrins.
  • Chemically and / or thermally modified starches eg. B. hydroxypropyl starch phosphate, dihydroxypropyl distarch phosphate or the commercial products Dry Flo ® .
  • Dextrans and their derivatives e.g. B. dextran sulfate.
  • nonionic cellulose derivatives such as methyl cellulose, hydroxypropyl cellulose or hydroxyethyl cellulose
  • cationic cellulose derivatives e.g. B. the commercial products Celquat ® and Polymer JR ® , and preferably Celquat ® H 100, Celquat ® L 200 and Polymer JR ® 400 (Poryquaternium-10) and Polyquaternium-24.
  • polysaccharides from fucose units e.g. B. the commercial product Fucogel ® .
  • the polysaccharides composed of amino sugar units in particular chitins and their deacetylated derivatives, the chito- sane, and mucopolysaccharides.
  • the preferred mucopoly saccharides according to the invention include hyaluronic acid and its derivatives, e.g. B. sodium hyaluronate or dimethylsilanol hyaluronate, and chondroitin and its derivatives, e.g. B. chondroitin sulfate.
  • the cosmetic and pharmaceutical preparations according to the invention can contain further plant extracts. They are usually produced by extracting the entire plant, but in individual cases also exclusively from flowers and / or leaves and / or seeds and / or other parts of plants. According to the invention, the extracts from the meristem, i.e.
  • Algae extracts can also be used to advantage.
  • the algae extracts used according to the invention come from green algae, brown algae, red algae or blue-green algae (cyanobacteria).
  • the algae used for the extraction can be of natural origin as well as obtained through biotechnological processes and, if desired, can be changed compared to the natural form.
  • the organisms can be changed genetically, by breeding or by cultivation in media enriched with selected nutrients.
  • Preferred algae extracts come from seaweed, blue-green algae, from the green algae Codium tomentosum and from the brown algae Fucus vesiculosus.
  • a particularly preferred algae extract comes from blue-green algae of the Spirulina species, which were cultivated in a magnesium-enriched medium.
  • the extracts from chamomile, spirulina, green tea, aloe vera, meristem, lily of the valley, apricot, marigold, guava, sweet potato, lime, mango, kiwi, cucumber, mallow, marshmallow and witch hazel are particularly preferred.
  • the cosmetic and pharmaceutical preparations according to the invention can also contain mixtures of several, in particular two, different plant extracts.
  • the cosmetic and pharmaceutical preparations according to the invention can contain further active ingredients, auxiliaries and additives, for example:
  • Vitamins, provitamins and vitamin precursors from groups A, C, E and F especially retinol (vitamin Ai) and its esters, e.g. the acetate and the palmitate, 3,4-didehydroretinol (vitamin A 2 ), ß-carotene (provitamin des Vitamin A- ⁇ ), ascorbic acid (vitamin C), and the palmitic acid esters, glucosides or phosphates of ascorbic acid, tocopherols, especially ⁇ -tocopherol and its esters, for.
  • B the acetate, nicotinate, phosphate and succinate
  • vitamin F which is understood to mean essential fatty acids, in particular linoleic acid, linolenic acid and arachidonic acid;
  • Antioxidants for example amino acids (e.g. glycine, histidine, tyrosine, tryptophan) and their derivatives, imidazoles (e.g. urocanic acid) and their derivatives, peptides such as D, L-carnosine, D-carnosine, L- Carnosine and its derivatives (e.g. anserine), chlorogenic acid and its derivatives, lipoic acid and its derivatives (e.g. dihydroliponic acid), aurothioglucose, propylthiouracil and other thiols (e.g.
  • amino acids e.g. glycine, histidine, tyrosine, tryptophan
  • imidazoles e.g. urocanic acid
  • peptides such as D, L-carnosine, D-carnosine, L- Carnosine and its derivatives (e.g. anserine)
  • chlorogenic acid and its derivatives e.g.
  • thioredoxin glutathione, cysteine, cystine, cystamine and their glycosyl, N-acetyl, methyl, ethyl, propyl, amyl, butyl and lauryl, palmitoyl, oleyl, ⁇ -linoleyl, cholesteryl and glyceryl esters) and their salts, dilauryl thiodipropionate, distearyl thiodipropionate , Thiodipropionic acid and its derivatives (esters, ethers, peptides, lipids, nucleotides, nucleosides and salts) as well as sulfoximine compounds (e.g.
  • buthionine sulfoximines in very low tolerable dosages (e.g. B. pmol to ⁇ mol / kg), further (Me tall) chelators (e.g. B. ⁇ -hydroxy fatty acids, palmitic acid, phytic acid, lactoferrin), humic acid, bile acid, bile extracts, bilirubin, biliverdin, EDTA, EGTA and their derivatives, unsaturated fatty acids and their derivatives (e.g.
  • ZnO, ZnS0 4 selenium and its derivatives (e.g. selenium methionine), stilbenes and their derivatives (e.g. stilbene oxide, trans-stilbene oxide) and the derivatives suitable as antioxidants ( Salts, esters, ethers, sugars, nucleotides, nucleosides, peptides and lipids) of these active substances,
  • Triterpenes especially triterpenic acids such as ursolic acid, rosmaric acid, betulinic acid, boswellic acid and bryonolic acid,
  • Monomeric catechins especially catechin and epicatechin, leukoanthocyanidins, catechin polymers (catechin tannins) and gallotannins,
  • Thickeners e.g. B. gelatin, vegetable gums such as agar agar, guar gum, alginates, xanthan gum, gum arabic, karaya gum or locust bean gum, natural and synthetic clays and layered silicates, e.g. B. bentonite, hectorite, montmorillonite or Laponite ® , fully synthetic hydrocolloids such.
  • Structurants such as maleic acid and lactic acid
  • Solvents, swelling and penetration substances such as ethanol, isopropanol, ethylene glycol, propylene glycol, propylene glycol monoethyl ether, glycerin and diethylene glycol, carbonates, hydrogen carbonates, guanidines, ureas and primary, secondary and tertiary phosphates Perfume oils, pigments and dyes for coloring the agent, substances for adjusting the pH, e.g. B.
  • ⁇ - and ß-hydroxycarboxylic acids complexing agents such as EDTA, NTA, ß-alaninediacetic acid and phosphonic acids, - opacifiers such as latex, styrene / PVP and styrene / acrylamide copolymers, pearlescent agents such as ethylene glycol mono- and distearate and PEG-3 distearate , Blowing agents such as propane-butane mixtures, N 2 0, dimethyl ether, C0 2 and air.
  • complexing agents such as EDTA, NTA, ß-alaninediacetic acid and phosphonic acids
  • - opacifiers such as latex, styrene / PVP and styrene / acrylamide copolymers
  • pearlescent agents such as ethylene glycol mono- and distearate and PEG-3 distearate
  • Blowing agents such as propane-butane mixtures, N 2 0, dimethyl ether, C0 2
  • Additives to the cosmetic or pharmaceutical skin treatment agents are selected from the vitamins, provitamins or vitamin precursors of the vitamin B group or their derivatives and the derivatives of 2-furanone.
  • the vitamin B group or the vitamin B complex include, among others
  • Vitamin Bi common name thiamine, chemical name 3 - [(4 ' -amino-2 ' - methyl-5 ' -pyrimidinyl) -methyl] -5- (2-hydroxyethyl) -4-methylthiazolium chloride.
  • Thiamine hydrochloride is preferably used in amounts of 0.05 to 1% by weight, based on the total agent.
  • Vitamin B 2 common name riboflavin, chemical name 7,8-dimethyl-10- (1-D-ribityl) -benzo [g] pteridine-2,4 (3 / - /, 10 / - /) - dione.
  • riboflavin comes e.g. B. in whey before, other riboflavin derivatives can be isolated from bacteria and yeast.
  • a stereoisomer of riboflavin which is also suitable according to the invention is lyxoflavin which can be isolated from fishmeal or liver and which carries a D-arabityl radical instead of D-ribityl.
  • Riboflavin or its derivatives are preferably used in amounts of 0.05 to 1% by weight, based on the total agent.
  • Vitamin B 3 The compounds nicotinic acid and nicotinamide (niacinamide) are often listed under this name.
  • the nicotinamide which is present in the cosmetic and pharmaceutical preparations according to the invention preferably in amounts of 0.05 to 1% by weight, based on the total composition, is preferred according to the invention.
  • Vitamin B 5 pantothenic acid and panthenol.
  • Panthenol is preferably used.
  • Derivatives of panthenol which can be used according to the invention are, in particular, the esters and ethers of panthenol and cationically derivatized panthenols.
  • derivatives of 2-furanone with the general structural formula (I) can also be used.
  • the 2-furanone derivatives in which the substituents R 1 to R 6 independently of one another are a hydrogen atom, a hydroxyl radical, a methyl, methoxy, aminomethyl or hydroxymethyl radical, a saturated or mono- or di-unsaturated, linear or branched C 2 -C - hydrocarbon residue, a saturated or mono- or di-unsaturated, branched or linear mono-, di- or trihydroxy-C 2 -C - hydrocarbon residue or a saturated or mono- or di-unsaturated, branched or linear mono-, di - Or triamino-C 2 -C - hydrocarbon residue.
  • the substituents R 1 to R 6 independently of one another are a hydrogen atom, a hydroxyl radical, a methyl, methoxy, aminomethyl or hydroxymethyl radical, a saturated or mono- or di-unsaturated, linear or branched C 2 -C - hydrocarbon residue, a saturated or mono- or di-unsaturated,
  • Particularly preferred derivatives are the commercially available substances dihydro-3-hydroxy-4,4-dimethyl-2 (3H) -furanone with the common name pantolactone (Merck), 4-hydroxymethyl- ⁇ -butyrolactone (Merck), 3.3 -Dimethyl-2-hydroxy- ⁇ -butyrolactone (Aldrich) and 2,5-dihydro-5-methoxy-2-furanone (Merck), all stereoisomers being expressly included.
  • the 2-furanone derivative which is extremely preferred according to the invention is pantolactone (dihydro-3-hydroxy-4,4-dimethyl-2 (3H) -furanone), where in formula (I) R 1 is a hydroxyl group, R 2 is a hydrogen atom, R 3 and R 4 represent a methyl group and R 5 and R 6 represent a hydrogen atom.
  • the stereoisomer (R) - pantolactone is formed when pantothenic acid is broken down.
  • the above-mentioned compounds of the vitamin B 5 type and the 2-furanone derivatives are preferably present in the cosmetic and pharmaceutical preparations according to the invention in a total amount of 0.05 to 10% by weight, based on the total composition. Total amounts of 0.1 to 5% by weight are particularly preferred.
  • Vitamin B 6 which does not mean a uniform substance, but rather the derivatives of 5-hydroxymethyl-2-methylpyridin-3-ol known under the trivial names pyridoxine, pyridoxamine and pyridoxal.
  • Vitamin ⁇ is preferably present in the cosmetic and pharmaceutical preparations according to the invention in amounts of 0.0001 to 1.0% by weight, in particular in amounts of 0.001 to 0.01% by weight.
  • Vitamin B 7 also known as vitamin H or "skin vitamin”.
  • Biotin is (3aS, 4S, 6a?) - 2-oxohexahydrothienol [3,4-c /] - imidazole-4-valeric acid.
  • the cosmetic and pharmaceutical preparations according to the invention preferably contain biotin in amounts of 0.0001 to 1.0% by weight, in particular in amounts of 0.001 to 0.01% by weight.
  • Panthenol, pantolactone, nicotinamide and biotin are very particularly preferred according to the invention.
  • the skin treatment compositions according to the invention can contain one or more film-forming, emulsion-stabilizing, thickening or adhesive polymers selected from natural and synthetic polymers, which can be cationic, anionic, amphoteric or non-ionic.
  • cationic polymers are polysiloxanes with quaternary groups, e.g. , The commercial products Q2-7224 (Dow Corning), Dow Corning ® 929 Emulsion (with Amodimethicone), SM-2059 (General Electric), SLM-55067 (Wacker) and Abil ® -Quat 3270 and 3272 (Th. Goldschmidt).
  • Preferred anionic polymers which can support the action of the active ingredient used according to the invention contain carboxylate and / or sulfonate groups and, for example, acrylic acid, methacrylic acid, crotonic acid, maleic anhydride and 2-acrylamido-2-methylpropanesulfonic acid as monomers.
  • the acidic groups can be present in whole or in part as sodium, potassium, ammonium, mono- or triethanolammonium salt.
  • Preferred monomers are 2-acrylamido-2-methylpropanesulfonic acid and acrylic acid.
  • anionic polymers contain 2-acrylamido-2-methylpropanesulfonic acid as the sole monomer or as comonomer, it being possible for the sulfonic acid group to be wholly or partly in salt form.
  • copolymers of at least one anionic monomer and at least one nonionic monomer are acrylamide, methacrylamide, acrylic acid ester, methacrylic acid ester, vinyl pyrrolidone, vinyl ether and vinyl ester.
  • Preferred anionic copolymers are acrylic acid-acrylamide copolymers and in particular polyacrylamide copolymers with monomers containing sulfonic acid groups.
  • a particularly preferred anionic copolymer consists of 70 to 55 mol% of acrylamide and 30 to 45 mol% of 2-acrylamido-2-methylpropanesulfonic acid, the sulfonic acid groups being wholly or partly as sodium, potassium, ammonium, mono- or triethanolammonium Salt.
  • This copolymer can also be crosslinked, the preferred crosslinking agents being polyolefinically unsaturated compounds such as tetraallyloxyethane, allyl sucrose, allylpentaerythritol and methylene bisacrylamide.
  • Such a polymer is contained in the commercial product Sepigel ® 305 from SEPPIC.
  • the use of this compound has proven to be particularly advantageous in the context of the teaching according to the invention.
  • Polysorbate-80 sodium acryloyldimethyltaurate copoly- mers have proven effective as inventively particularly.
  • Other particularly preferred anionic homopolymers and copolymers are uncrosslinked and crosslinked polyacrylic acids. Allyl ethers of pentaerythritol, sucrose and propylene can be preferred crosslinking agents.
  • Such compounds are, for example, the commercial products Carbopol ® .
  • a particularly preferred anionic copolymer contains as monomer to 80-98% unsaturated, optionally substituted C 3 - 6 carboxylic acid or its anhydride as well as 2-20% optionally substituted acrylate of saturated C ⁇ o- 3 o-carboxylic acids, wherein the copolymer having the The aforementioned networking agents can be networked.
  • Corresponding commercial products are Pemulen ® and the Carbopol ® types 954, 980, 1342 and ETD 2020 (ex BF Goodrich).
  • Suitable nonionic polymers are, for example, polyvinyl alcohols, which can be partially saponified, e.g. B. the commercial products Mowiol ® and vinyl pyrrolidone / vinyl ester copolymers and polyvinyl pyrrolidones, which, for. B. are sold under the trademark Luviskol ® (BASF).
  • the pharmaceutical preparations according to the invention are also administered enterally, parenterally or rectally.
  • the pharmaceutical preparations can be in the form of tablets, capsules, dragees, syrups, suspensions, solutions, powders, granules or emulsions.
  • the preparations may be in the form of solutions or suspensions for perfusion or injection.
  • the preparations can be in the form of suppositories for administration by the rectal route.
  • the active ingredients for. B. with corn starch, milk sugar, cane sugar, sorbitol, microcrystalline cellulose, magnesium stearate, polyvinylpyrrolidone, citric acid, tartaric acid, water, water / ethanol, water / glycerol, water / sorbitol, water / polyethylene glycol, Incorporate propylene glycol, carboxymethyl cellulose or fat-containing substances such as hard fat or their suitable mixtures into conventional galenical preparations such as tablets, dragees, capsules, powders, suspensions, drops, ampoules, juices or suppositories.
  • inert customary carriers and / or diluents for. B. with corn starch, milk sugar, cane sugar, sorbitol, microcrystalline cellulose, magnesium stearate, polyvinylpyrrolidone, citric acid, tartaric acid, water, water / ethanol, water / glycerol, water / sorbitol, water
  • the daily dosage of the mixture of active substances required to achieve a corresponding effect in pharmaceutical applications consists of the substances with a stimulating and / or depolarizing effect on the C-nerve fibers, the phosphodiesterase inhibitors and the substances with an anti-estrogenic effect is expediently 0.1 to 10 mg / kg body weight, preferably 0.5 to 2 mg / kg body weight.
  • the pharmaceutical preparations according to the invention are preferably suitable for the therapeutic treatment of cellulite.
  • Another object of the invention is accordingly the use of a combination of active ingredients
  • compositions according to the invention are prepared in such a way that the aqueous phase, which contains water-soluble active ingredients and ingredients and, if appropriate, water-soluble emulsifiers, and the oil phase which contains fats, oils, oil-soluble active ingredients and optionally oil-soluble emulsifiers, at a temperature of 10 to 90 ° C are mixed intensively.
  • the anti-cellulite gel according to Example 1 with the formulation Gel-5 was tested for its effectiveness in relation to the cellulite phenomenon and its cosmetic acceptance in 25 women (half-side test against placebo).
  • the test participants were asked directly after the use test about the effectiveness of the product and the cosmetic acceptance in a standardized way.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

L'invention concerne des préparations cosmétiques et pharmaceutiques contenant une matière qui stimule et/ou dépolarise les fibres nerveuses C, un inhibiteur de phosphodiestérase et une matière ayant une action anti-oestrogène. Ces préparations conviennent notamment au traitement de la cellulite.
PCT/EP2001/002071 2000-02-28 2001-02-23 Preparations cosmetiques et pharmaceutiques destinees au traitement de la cellulite Ceased WO2001064167A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP01907556A EP1261310A1 (fr) 2000-02-28 2001-02-23 Preparations cosmetiques et pharmaceutiques destinees au traitement de la cellulite
AU2001235491A AU2001235491A1 (en) 2000-02-28 2001-02-23 Cosmetic and pharmaceutical preparations for treating cellulite

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE2000109423 DE10009423A1 (de) 2000-02-28 2000-02-28 Kosmetische und pharmazeutische Zubereitungen
DE10009423.6 2000-02-28

Publications (1)

Publication Number Publication Date
WO2001064167A1 true WO2001064167A1 (fr) 2001-09-07

Family

ID=7632756

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/002071 Ceased WO2001064167A1 (fr) 2000-02-28 2001-02-23 Preparations cosmetiques et pharmaceutiques destinees au traitement de la cellulite

Country Status (4)

Country Link
EP (1) EP1261310A1 (fr)
AU (1) AU2001235491A1 (fr)
DE (1) DE10009423A1 (fr)
WO (1) WO2001064167A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10218476A1 (de) * 2002-04-25 2003-11-06 Beiersdorf Ag Zubereitungen mit Lignanen
DE10329004A1 (de) * 2003-06-27 2005-01-13 Kaanya Cosmetics Gmbh Kosmetisches Verfahren zur Verminderung sichtbarer Alterungszeichen der Haut
US9125816B2 (en) 2000-08-30 2015-09-08 Besins Healthcare Inc. Pharmaceutical composition and method for treating hypogonadism
BE1026340B1 (nl) * 2018-10-22 2020-01-07 Sylphar Nv Samenstelling voor lokale cutane toediening en gebruik daarvan
WO2022204757A1 (fr) * 2021-03-30 2022-10-06 Noxopharm Limited Formulation d'isoflavone améliorée

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2841470B1 (fr) * 2002-06-27 2006-01-13 Pharmascience Lab Utilisation d'isoflavones pour la preparation de compositions topiques utiles pour favoriser l'amincissement et methode de traitement cosmetique associee
WO2006063714A1 (fr) 2004-12-14 2006-06-22 Menarini Ricerche S.P.A. Préparations pharmaceutiques pour le traitement de la cellulite
DE102006050984A1 (de) * 2006-10-26 2008-04-30 Henkel Kgaa Leistungsgesteigerte kosmetische Mittel mit Purin und/oder Purinderivaten
DE102006060439A1 (de) 2006-12-19 2008-06-26 Henkel Kgaa Verbesserung der Hautverträglichkeit von hyperämisierenden Wirkstoffen
EP2295031B1 (fr) 2009-08-05 2018-01-10 Symrise AG Utilisation de ptérocarpanes comme agents actifs anticellulite
WO2013112040A1 (fr) 2012-01-27 2013-08-01 Biotropics Malaysia Berhad Utilisation de certains dérivés de benzène trioxigéné dans la gestion de graisse corporelle

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0692250A2 (fr) * 1994-07-12 1996-01-17 INDENA S.p.A. Formulations contenant de l'esculoside et leur utilisation dans les domaines pharmaceutiques et cosmétiques
WO1996010387A2 (fr) * 1994-09-30 1996-04-11 The Boots Company Plc Composition pour stimulant capillaire
WO1998000101A1 (fr) * 1996-06-27 1998-01-08 Indústria e Comércio de Cosméticos Natura Ltda. Compositions cosmetiques pour le soin de la peau, notamment comme agent anticellulite ou reducteur de cellulite
EP1020192A2 (fr) * 1999-01-11 2000-07-19 Michael Schneider Composition anti-cellulitique

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001500841A (ja) * 1996-03-29 2001-01-23 エス ヴェー パテントフェアヴェアツングス ゲゼルシャフト ミット ベシュレンクテル ハフツンク 障害された皮下結合脂肪組織、とりわけ脂肪性浮腫の場合における皮膚を引きしめ滑らかにするための化粧品および化粧用組成物
JP3667503B2 (ja) * 1997-08-26 2005-07-06 花王株式会社 皮膚化粧料
KR20010041938A (ko) * 1998-03-16 2001-05-25 데이비드 엠 모이어 피부 외형을 조절하는 방법

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0692250A2 (fr) * 1994-07-12 1996-01-17 INDENA S.p.A. Formulations contenant de l'esculoside et leur utilisation dans les domaines pharmaceutiques et cosmétiques
WO1996010387A2 (fr) * 1994-09-30 1996-04-11 The Boots Company Plc Composition pour stimulant capillaire
WO1998000101A1 (fr) * 1996-06-27 1998-01-08 Indústria e Comércio de Cosméticos Natura Ltda. Compositions cosmetiques pour le soin de la peau, notamment comme agent anticellulite ou reducteur de cellulite
EP1020192A2 (fr) * 1999-01-11 2000-07-19 Michael Schneider Composition anti-cellulitique

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DI SALVO ET AL: "Cellulitis control. Efficacy of xanthines, silanes, CoA, L-carnitine and herbal extracts in reducing cellulitis", STN CAPLUS, XP002126524 *
WOODRUFF J: "LIGHTENING SKIN AND LESSENING CELLULITE", MANUFACTURING CHEMIST,GB,MORGAN-GRAMPIAN LTD. LONDON, vol. 67, no. 4, 1 April 1996 (1996-04-01), pages 38 - 39,41, XP000683051, ISSN: 0262-4230 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9125816B2 (en) 2000-08-30 2015-09-08 Besins Healthcare Inc. Pharmaceutical composition and method for treating hypogonadism
US9132089B2 (en) 2000-08-30 2015-09-15 Besins Healthcare Inc. Pharmaceutical composition and method for treating hypogonadism
DE10218476A1 (de) * 2002-04-25 2003-11-06 Beiersdorf Ag Zubereitungen mit Lignanen
DE10329004A1 (de) * 2003-06-27 2005-01-13 Kaanya Cosmetics Gmbh Kosmetisches Verfahren zur Verminderung sichtbarer Alterungszeichen der Haut
BE1026340B1 (nl) * 2018-10-22 2020-01-07 Sylphar Nv Samenstelling voor lokale cutane toediening en gebruik daarvan
WO2022204757A1 (fr) * 2021-03-30 2022-10-06 Noxopharm Limited Formulation d'isoflavone améliorée

Also Published As

Publication number Publication date
AU2001235491A1 (en) 2001-09-12
DE10009423A1 (de) 2001-09-06
EP1261310A1 (fr) 2002-12-04

Similar Documents

Publication Publication Date Title
EP1259221A1 (fr) Utilisation de flavones ou d'isoflavones pour le traitement de la cellulite
EP1658088B1 (fr) Composition avec un effect prebiotique comprenant des extraits de pinus sylvestris et de ribes nigrum pour l'inhibition de la croissance de priopionibacterium acnes
DE69718240T2 (de) Hemmung der abnormalen Anhäufung von extrazellulärer Matrix
DE10333245C5 (de) Präbiotisch wirksame Pflanzenextrakte
EP1002526B1 (fr) Composition pour le blanchiment de la peau contenant un extrait de busserole et un réducteur
DE69810649T2 (de) Verwendung von ellagsäure und ihren derivaten in der kosmetik und der dermatologie
DE10063433A1 (de) Verwendung von DNA-Reparatur-Enzymen als MMP-1-Inhibitoren
DE102004011968A1 (de) Präbiotisch wirksame Pflanzenextrakte
DE4341000A1 (de) Verwendung von L-Arginin, L-Ornithin oder L-Citrullin und topischen Zubereitungen mit diesen Stoffen
EP1352640A1 (fr) Compositions pouvant retarder le vieillissement de la peau
KR20140119669A (ko) Ｈａｓ2-자극용 식물 추출물
EP2395966B1 (fr) Préparation cosmétique pour le soin de la peau
JP2937446B2 (ja) 白髪防止黒化剤
EP1261310A1 (fr) Preparations cosmetiques et pharmaceutiques destinees au traitement de la cellulite
JPH07223933A (ja) 美白剤および皮膚外用剤
JP3900388B2 (ja) 美白剤および美白化粧料
CN112569163B (zh) 一种不含防腐剂的抗敏修复乳液及其制备方法
KR101830864B1 (ko) 탈모방지 또는 모발 성장 촉진용 화장료 조성물
KR20120139222A (ko) 탄시논ⅱａ를 유효성분으로 함유하는 피부 외용제 조성물
KR101156968B1 (ko) 멜라노사이트의 수상돌기 신장 억제제 및 이를 함유하는 피부 외용제
WO2005030157A1 (fr) Preparations cosmetiques ou dermatologiques a teneur en isoflavones et en licochalcone a
KR101156970B1 (ko) 멜라노사이트의 수상돌기 신장 억제제 및 이를 함유하는피부 외용제
KR102780319B1 (ko) 동백나무 과피 추출물을 유효성분으로 포함하는 두피 개선용 조성물
DE10340684A1 (de) Neue Verwendungen von Vitamin B6 in kosmetischen oder pharmazeutischen Zusammensetzungen
EP4059508A1 (fr) Procédés d'utilisation de compositions comprenant un extrait de lichen d'islande

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BR CA CN CZ HU JP MX NO PL SK US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001907556

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001907556

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2001907556

Country of ref document: EP